Aethlon Medical, Inc. (AEMD)
AEMD Price and Sentiment
AEMD Latest news
Aethlon Medical, Inc. (AEMD) CEO Charles Fisher on Q2 2022 Results - Earnings Call Transcript
2021-11-09 22:38Aethlon Medical, Inc. (AEMD) CEO Charles Fisher on Q2 2022 Results - Earnings Call Transcript
Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update
2021-11-09 16:15SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious diseases, today reported financial results for its second quarter ended September 30, 2021 and provided an update on recent developments. Company Updates Aethlon Medical is continuing the research and clinical development of the Hemopurifier™, our therapeutic blood filtration system that can bind and remove life-threatening viruses and harmful exosomes from blood.
Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 9, 2021
2021-11-02 08:02SAN DIEGO, Nov. 2, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its second quarter fiscal year 2022, ended September 30, 2021, at 4:15 p.m. EST on Tuesday, November 9, 2021.
Aethlon Medical Announces Peer-Reviewed Publication of Two Case Studies of Critically Ill COVID-19 Patients Treated with the Hemopurifier®
2021-10-12 08:01SAN DIEGO, Oct. 12, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced the publication of a manuscript in the peer-reviewed journal Frontiers in Medicine describing two cases of critically ill COVID-19 patients treated with the Hemopurifier®, Aethlon's therapeutic blood filtration system. The publication, titled "Removal of COVID-19 spike protein, whole virus, exosomes and exosomal microRNAs by the Hemopurifier® lectin-affinity cartridge in critically Ill patients with COVID-19 infection," is available here: https://www.frontiersin.org/articles/10.3389/fmed.2021.744141/full The publication documents two critically ill COVID-19 patients receiving a combined total of nine, six-hour Hemopurifier® treatment sessions.
Aethlon Medical Announces Contracting with PPD to Advance Hemopurifier Clinical Programs
2021-09-30 08:02SAN DIEGO, Sept. 30, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it has entered into an agreement with PPD, Inc. (Nasdaq: PPD), a leading global contract research organization (CRO), for PPD to oversee the company's clinical studies investigating the Hemopurifier, Aethlon's therapeutic blood filtration system, for infectious disease indications.
8 Things to Know About Aethlon Medical as Investors Send AEMD Stock Soaring Today
2021-09-22 11:08Aethlon Medical (AEMD) stock is rising higher on Wednesday due to heavy trading despite a lack of news from the company. The post 8 Things to Know About Aethlon Medical as Investors Send AEMD Stock Soaring Today appeared first on InvestorPlace.
Aethlon Medical to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
2021-09-07 08:01SAN DIEGO, Sept. 7, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced that it will be presenting at the H.C.
Aethlon Medical, Inc. (AEMD) CEO Chuck Fisher on Q1 2021 Results - Earnings Call Transcript
2021-08-09 20:49Aethlon Medical, Inc. (AEMD) CEO Chuck Fisher on Q1 2021 Results - Earnings Call Transcript
Aethlon Medical Announces First Quarter Financial Results and Provides Corporate Update
2021-08-09 16:15SAN DIEGO, Aug. 9, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its first quarter ended June 30, 2021 and provided an update on recent developments. Company Updates Aethlon Medical is continuing the research and clinical development of our Hemopurifier to bind and remove COVID-19 viral particles, including many variant COVID-19 particles of interest and related exosomes.
Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 9, 2021
2021-07-29 13:32SAN DIEGO, July 29, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its first quarter fiscal year 2022, ended June 30, 2020, at 4:15 p.m. EST on Monday, August 9, 2021.